Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 11, 2006, Pages 4635-4640

  Paisley, A N ^a   O'Callaghan, C J ^b   Lewandowski, K C ^c   Parkinson, C ^d   Roberts, M E ^a   Drake, W M ^e   Monson, J P ^e   Trainer, P J ^a   Randeva, Harpal S ^f,g  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b QUEEN S UNIVERSITY   (Canada)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d IPSWICH HOSPITAL   (United Kingdom)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF WARWICK   (United Kingdom)

^g UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; PEGVISOMANT; SOMATOMEDIN C; VASCULOTROPIN;

ACROMEGALY; ADULT; ARTICLE; BLOOD ANALYSIS; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ANALYSIS; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 33751528568     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2589     Document Type: Article

References (38)

1. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK 1994 Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41:95-102
2. Colao A, Ferone D, Marzullo P, Lombardi G 2004 Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102-152
3. Colao A, Marzullo P, Di Somma C, Lombardi G 2001 Growth hormone and the heart. Clin Endocrinol (Oxf) 54:137-154
4. Vianna CB, Vieira ML, Mady C, Liberman B, Durazzo AE, Knoepfelmacher M, Salgado LR, Ramires JA 2002 Treatment of acromegaly improves myocardial abnormalities. Am Heart J 143:873-876
5. Colao A, Vitale G, Pivonello R, Ciccarelli A, Di Somma C, Lombardi G 2004 The heart: an end-organ of GH action. Eur J Endocrinol 151(Suppl 1):S93-S101
6. Colao A, Spiezia S, Cerbone G, Pivonello R, Marzullo P, Ferone D, Di Somma C, Assanti AP, Lombardi G 2001 Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol (Oxf) 54:515-524
7. Colao A, Marzullo P, Lombardi G 2002 Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 146:303-309
8. Maison P, Demolis P, Young J, Schaison G, Giudicelli JF, Chanson P 2000 Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin Endocrinol (Oxf) 53:445-451
9. Brevetti G, Marzullo P, Silvestro A, Pivonello R, Oliva G, Di Somma C, Lombardi G, Colao A 2002 Early vascular alterations in acromegaly. J Clin Endocrinol Metab 87:3174-3179
10. Lie JT 1980 Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J 100:41-52
11. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ 2001 Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 89:201-210
12. Galis ZS, Sukhova GK, Lark MW, Libby P 1994 Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94:2493-2503
13. Mun-Bryce S, Rosenberg GA 1998 Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 18:1163-1172
14. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R 2002 Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106:1543-1549
15. Shah PK 2000 Plaque disruption and thrombosis: potential role of inflammation and infection. Cardiol Rev 8:31-39
16. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Yeno T, Sugi K, Imaizumi T 1998 Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32:368-372
17. Wainwright CL 2004 Matrix metalloproteinases, oxidative stress and the acute response to acute myocardial ischaemia and reperfusion. Curr Opin Pharmacol 4:132-138
18. Dollery CM, McEwan JR, Henney AM 1995 Matrix metalloproteinases and cardiovascular disease. Circ Res 77:863-868
19. Wang H, Keiser JA 1998 Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res 83:832-840
20. Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A 2002 Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 87:1692-1699
21. Jaffrain-Rea ML, Minniti G, Moroni C, Esposito V, Ferretti E, Santoro A, Infusino T, Tamburrano G, Cantore G, Cassone R 2003 Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur J Endocrinol 148:193-201
22. Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM, Trainer PJ 2002 Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol (Oxf) 56:303-311
23. Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ 2003 Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 88:5650-5655
24. Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP, Trainer PJ 2003 Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 149:521-527
25. Trainer PJ, Drake WM, Perry LA, Taylor NF, Besser GM, Monson JP 2001 Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. J Clin Endocrinol Metab 86:2989-2992
26. Trainer PJ 2002 Editorial: acromegaly - consensus, what consensus? J Clin Endocrinol Metab 87:3534-3536
27. Nagai Y, Ando H, Nohara E, Yamashita H, Takamura T, Kobayashi K 2000 Plasma levels of vascular endothelial growth factor in patients with acromegaly. Horm Metab Res 32:326-329
28. Punglia RS, Lu M, Hsu J, Kuroki M, Tolentino MJ, Keough K, Levy AP, Levy NS, Goldberg MA, D'Amato RJ, Adamis AP 1997 Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 46:1619-1626
29. Vitale G, Pivonello R, Galderisi M, D'Errico A, Spinelli L, Lupoli G, Lombardi G, Colao A 2001 Cardiovascular complications in acromegaly: methods of assessment. Pituitary 4:251-257
30. Clayton RN 2003 Cardiovascular function in acromegaly. Endocr Rev 24:272-277
31. Randeva HS, Lewandowski KC, Komorowski J, Murray RD, O'Callaghan CJ, Hillhouse EW, Stepien H, Shalet SM 2004 Growth hormone replacement decreases plasma levels of matrix metalloproteinases (2 and 9) and vascular endothelial growth factor in growth hormone-deficient individuals. Circulation 109:2405-2410
32. Shweiki D, Itin A, Soffer D, Keshet E 1992 Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845
33. Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, Kim RY, Rohan RM, Colby KA, Yeo KT, Adamis AP 1996 Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 98:1667-1675
34. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA, Roelfsema F 2004 Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 89:2789-2796
35. Kawamoto H, Uozumi T, Kawamtot K, Arita K, Yano T, Hirohata T 1996 Type IV collagenase activity and cavernous sinus invasion in human pituitary adenomas. Acta Neurochir (Wien) 138:390-395
36. Pereda MP, Ledda MF, Goldberg V, Chervin A, Carrizo G, Molina H, Muller A, Renner U, Podhajcer OO, Arzt E, Stalla GK 2000 High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells. J Clin Endocrinol Metab 84:263-269
37. Turner HE, Nagy ZS, Esiri MM, Harris AL, Wass JAH 2000 Role of matrix metalloproteinase 9 in pituitary tumors. J Clin Endocrinol Metab 85:2931-2935
38. Turner HE, Harris AL, Melmed S, Wass JAH 2003 Angiogenesis in endocrine tumors. Endocr Rev 24:600-632